Quick Answer
TherapeuticsMD, Inc. reported Net Income Loss of -$569.0 thousand for the year ending 2025.
- TherapeuticsMD, Inc. showed an increase of +73.9% in Net Income Loss from 2024 to 2025.
- This data is from TherapeuticsMD, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$21.09 million | Q3 2016: -$25.02 million | Q4 2016: -$22.84 million | Q1 2017: -$21.16 million | Q2 2017: -$19.68 million | Q3 2017: -$14.67 million | Q4 2017: -$21.43 million | Q1 2018: -$24.40 million | Q2 2018: -$33.22 million | Q3 2018: -$35.61 million | Q4 2018: -$39.39 million | Q1 2019: -$39.51 million | Q2 2019: -$55.24 million | Q3 2019: -$31.97 million | Q4 2019: -$49.44 million | Q1 2020: -$56.85 million | Q2 2020: -$51.98 million | Q3 2020: -$32.61 million | Q4 2020: -$42.09 million | Q1 2021: -$39.38 million | Q2 2021: -$42.65 million | Q3 2021: -$47.42 million | Q4 2021: -$42.96 million | Q1 2022: -$49.02 million | Q2 2022: $112.28 million | Q3 2022: -$28.97 million | Q1 2023: -$3.60 million | Q2 2023: -$2.41 million | Q3 2023: -$3.38 million | Q1 2024: -$734.0 thousand | Q2 2024: -$1.09 million | Q3 2024: -$609.0 thousand | Q1 2025: -$653.0 thousand | Q2 2025: $551.0 thousand | Q3 2025: $152.0 thousand.
- Over the full 16 years of available data (2010 to 2025), TherapeuticsMD, Inc.'s Net Income Loss has grown by 80.2%.
- Historical annual values: Fiscal year 2025: -$569.0 thousand | Fiscal year 2024: -$2.18 million | Fiscal year 2023: -$10.28 million | Fiscal year 2022: $112.00 million | Fiscal year 2021: -$172.42 million | Fiscal year 2020: -$183.52 million | Fiscal year 2019: -$176.15 million | Fiscal year 2018: -$132.62 million | Fiscal year 2017: -$76.93 million | Fiscal year 2016: -$89.88 million | Fiscal year 2015: -$85.08 million | Fiscal year 2014: -$54.22 million | Fiscal year 2013: -$28.42 million | Fiscal year 2012: -$35.12 million | Fiscal year 2011: -$12.91 million | Fiscal year 2010: -$2.87 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: